Medesis Pharma SA (ALMDP) - Net Assets

Latest as of June 2024: €-5.10 Million EUR ≈ $-5.96 Million USD

Based on the latest financial reports, Medesis Pharma SA (ALMDP) has net assets worth €-5.10 Million EUR (≈ $-5.96 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.11 Million ≈ $2.46 Million USD) and total liabilities (€7.20 Million ≈ $8.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medesis Pharma SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-5.10 Million
% of Total Assets	-242.03%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

Medesis Pharma SA - Net Assets Trend (2018–2023)

This chart illustrates how Medesis Pharma SA's net assets have evolved over time, based on quarterly financial data. Also explore ALMDP current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Medesis Pharma SA (2018–2023)

The table below shows the annual net assets of Medesis Pharma SA from 2018 to 2023. For live valuation and market cap data, see ALMDP company net worth.

Year	Net Assets	Change
2023-12-31	€-4.50 Million ≈ $-5.26 Million	-325.38%
2022-12-31	€-1.06 Million ≈ $-1.24 Million	-164.26%
2021-12-31	€1.65 Million ≈ $1.92 Million	+179.04%
2020-12-31	€-2.08 Million ≈ $-2.43 Million	+13.87%
2019-12-31	€-2.42 Million ≈ $-2.83 Million	-176.03%
2018-12-31	€-876.00K ≈ $-1.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Medesis Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2071236900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component	Amount	Percentage
Common Stock	€2.48 Million	%
Other Components	€14.75 Million	%
Total Equity	€-4.50 Million	100.00%

Medesis Pharma SA Competitors by Market Cap

The table below lists competitors of Medesis Pharma SA ranked by their market capitalization.

Company	Market Cap
Kore Potash Plc LSE:KP2	$1.80 Million
Proven Growth and Income Vct PLC LSE:PGOO	$1.81 Million
Canzon Israel Ltd TA:CNZN	$1.81 Million
Oldfields Holdings Ltd AU:OLH	$1.81 Million
Engold Mines Inc V:EGM	$1.80 Million
Seoul Food Ind Co Ltd KO:004415	$1.80 Million
Prosper Gold Corp. V:PGX	$1.79 Million
MJ Gleeson plc LSE:GLE	$1.79 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medesis Pharma SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2022 to 2023, total equity changed from -1,057,832 to -4,499,849, a change of -3,442,017.
Net loss of 3,959,491 reduced equity.
Other factors increased equity by 517,474.

Equity Change Factors (2022 to 2023)

Factor	Impact	Contribution
Net Income	€-3.96 Million	-87.99%
Other Changes	€517.47K	+11.5%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares Medesis Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2018-12-31	€-0.21	€0.35	x
2019-12-31	€-0.81	€0.35	x
2020-12-31	€-0.64	€0.35	x
2021-12-31	€0.38	€0.35	x
2022-12-31	€-0.24	€0.35	x
2023-12-31	€-0.91	€0.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medesis Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1319.68%
• Asset Turnover: 0.16x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-26.82%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2018	0.00%	-9290.91%	0.01x	0.00x	€-934.40K
2019	0.00%	-469.13%	0.32x	0.00x	€-837.20K
2020	0.00%	-406.27%	0.25x	0.00x	€-638.82K
2021	-160.89%	-2766.62%	0.02x	2.63x	€-2.81 Million
2022	0.00%	-5841.88%	0.02x	0.00x	€-2.66 Million
2023	0.00%	-1319.68%	0.16x	0.00x	€-3.51 Million

Industry Comparison

This section compares Medesis Pharma SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $11,454,345
Average return on equity (ROE) among peers: -119.88%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medesis Pharma SA (ALMDP)	€-5.10 Million	0.00%	N/A	$1.80 Million
Abionyx Pharma SA (ABNX)	$7.17 Million	-58.67%	1.21x	$123.48 Million
Abivax SA (ABVX)	$33.94 Million	-14.97%	0.12x	$6.97 Billion
Adocia (ADOC)	$6.33 Million	-368.23%	6.13x	$109.57 Million
Aelis Farma SA (AELIS)	$1.20 Million	-263.37%	5.00x	$18.95 Million
Biophytis S.A. (ALBPS)	$-409.32K	0.00%	0.00x	$1.03 Million
Cellectis (ALCLS)	$5.96 Million	0.00%	0.87x	$271.40 Million
Advicenne (ALDVI)	$29.63 Million	-15.61%	0.12x	$14.80 Million
Genoway (ALGEN)	$18.57 Million	9.86%	0.71x	$30.11 Million
Integragen (ALINT)	$691.87K	-367.93%	7.36x	$1.00 Million

About Medesis Pharma SA

PA:ALMDP France Biotechnology

Market Cap

$2.11 Million

€1.80 Million EUR

Market Cap Rank

#29775 Global

#559 in France

Share Price

€0.35

Change (1 day)

+0.00%

52-Week Range

€0.35 - €0.35

All Time High

€16.80